Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1Gynecologic 1

Conditions

Keratosis, Actinic 7Melanoma 3Uveal Melanoma 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Ovarian Neoplasms 1Nonmelanoma Skin Cancers 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Basal Cell Nevus Syndrome 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Solutions × Dermatologic × Clear all
NCT04752826 2026-02-18

MK-3475-D20

BioInvent International AB

Phase 1/2 Recruiting
176 enrolled
DermatologicGynecologicLymphoid

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT07230613 2026-02-11

NEOREM-NEO-1

UNICANCER

Phase 2 Recruiting
50 enrolled
Dermatologic

Melanoma

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

BioInvent International AB

Phase 1/2 Active not recruiting
35 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡